Septerna, Inc. (NASDAQ:SEPN) CFO Buys $29,250.00 in Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The stock was purchased at an average cost of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the purchase, the chief financial officer now owns 30,000 shares of the company’s stock, valued at $175,500. This trade represents a 20.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Septerna Trading Down 1.5 %

Septerna stock opened at $5.80 on Monday. Septerna, Inc. has a fifty-two week low of $4.17 and a fifty-two week high of $28.99. The firm’s 50 day moving average price is $17.78.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target on the stock. TD Cowen assumed coverage on Septerna in a report on Tuesday, November 19th. They set a “buy” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $50.00 price objective on shares of Septerna in a report on Tuesday, February 11th. Finally, Wells Fargo & Company cut Septerna from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $43.00 to $14.00 in a research note on Tuesday, February 18th.

Institutional Trading of Septerna

Several hedge funds and other institutional investors have recently made changes to their positions in SEPN. Tower Research Capital LLC TRC bought a new position in Septerna in the 4th quarter worth about $25,000. New York State Common Retirement Fund purchased a new stake in shares of Septerna during the fourth quarter valued at approximately $32,000. Legal & General Group Plc purchased a new stake in shares of Septerna during the fourth quarter valued at approximately $42,000. Summit Investment Advisors Inc. purchased a new position in Septerna in the 4th quarter worth approximately $45,000. Finally, BNP Paribas Financial Markets bought a new position in Septerna in the 4th quarter valued at approximately $52,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.